Profil
Barbara Brunnhuber is the founder and currently serves as the Chief Executive Officer & Managing Director of Mireca Medicines GmbH, which she founded in 2017.
She also previously worked as the Head of Operations at to-BBB technologies BV.
Aktive Positionen von Barbara Brunnhuber
| Unternehmen | Position | Beginn |
|---|---|---|
Mireca Medicines GmbH
 Mireca Medicines GmbH Pharmaceuticals: MajorHealth Technology Mireca Medicines GmbH develops treatment for hereditary eye disease. The company was founded by François Paquet-Durand, Pieter Jaap Gaillard and Barbara Brunnhuber in 2017 and is headquartered in Tubingen, | Vorstandsvorsitzender | 01.03.2017 |
Ehemalige bekannte Positionen von Barbara Brunnhuber
| Unternehmen | Position | Ende |
|---|---|---|
to-BBB technologies BV
 to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Geschäftsführer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
to-BBB technologies BV
to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
Mireca Medicines GmbH
Mireca Medicines GmbH Pharmaceuticals: MajorHealth Technology Mireca Medicines GmbH develops treatment for hereditary eye disease. The company was founded by François Paquet-Durand, Pieter Jaap Gaillard and Barbara Brunnhuber in 2017 and is headquartered in Tubingen, | Health Technology |
